Advanced search
Publication Cover
Expert Review of Hematology Volume 9, 2016 - Issue 1
Submit an article Journal homepage
641
Views
6
CrossRef citations to date
0
Altmetric
Review

Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure

Holger SchmidClinic and Policlinic IV, Section of Nephrology, Munich University Hospital, Munich, Germany;KFH Nierenzentrum Muenchen Laim, Munich, GermanyCorrespondence[email protected]
Pages 5-20 | Published online: 17 Nov 2015

References

  • Papers of special note have been highlighted as:
  • (•)     of interest
  • (••)   of considerable interest.
  • US Renal Data System. CKD in the United States: an overview of the USRDS Annual Data Report, volume 1. Am J Kid Dis. 2015;66(Suppl 1): S1–S10.
  • Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–174.
  • Snyder JJ, Collins AJ. Association of preventive health care with atherosclerotic heart disease and mortality in CKD. J Am Soc Nephrol. 2009;20(7):1614–1622.
  • Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38(4):803–812.
  • Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens. 2002;11(3):337–341.
  • Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med. 1989;110(2):108–114.
  • Moreno F, Aracil FJ, Perez R, et al. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis. 1996;27:548–556.
  • Jurkovitz CT, Abramson JL, Vaccarino V, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–2925.
  • World Health Organization. Nutritional anaemias: report of a WHO scientific group. Geneva: World Health Organization; 1968.
  • KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471.
  • KDIGO Clinical Practice Guidelines for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:288.
  • Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–1359.
  • Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.

•• An early, ground-breaking trial demonstrating that in hemodialysis (HD) patients with heart disease administration of epoetin to target a near normal hematocrit is not recommended.

• A pivotal trial in chronic kidney disease (CKD) patients not on dialysis, showing a higher mortality risk in patients with complete anemia correction compared to those with partial anemia correction.

  • Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.

• Another pivotal trial comparing partial versus complete anemia correction in CKD patients not on dialysis, demonstrating no reduction of cardiovascular events after early complete correction.

  • Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

• A large trial in diabetic CKD patients not on dialysis reporting that darbepoetin alfa compared to placebo did not reduce the risk of either death or a cardiovascular event or death or a renal event, but increased the risk of stroke.

  • Hanafusa Nomura T, Hasegawa T, Nangaku M. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant. 2014;29(12):2316–2326.
  • Turenne MN, Cope EL, Porenta S, et al. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? J Am Soc Nephrol. 2015;26(3):754–764.
  • Regidor D, McClellan WM, Kewalramani R, et al. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant. 2011;26(5):1583–1591.
  • Jelkmann W. Recombinant EPO production—points the nephrologist should know. Nephrol Dial Transplant. 2007;22:2749–275.
  • Schmid H. Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother. 2013;14(7):937–948.
  • Bennett CL, Jacob S, Hymes J, et al. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014;370(21):2055–2056.
  • Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436–440.
  • Jarsch M, Brandt M, Lanzendörfer M, et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81:63–69.
  • Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–1215.

••A seminal report in anemic peritoneal dialysis patients demonstrating the feasibility of extended methoxy polyethylene glycol-epoetin beta (MPG-EPO) administration intervals.

  • Veng-Pedersen P, Freise KJ, Schmidt RL, et al. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. J Pharm Pharmacol. 2008;60:1321–1334.
  • El-Komy MH, Widness JA, Veng-Pedersen P. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metab Dispos. 2011;39:603–609.
  • Fishbane S, Pannier A, Liogier X, et al. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol. 2007;47(11):1390–1397.
  • Del Vecchio L, Cavalli A, Locatelli F. Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease. Drugs Today (Barc). 2008;44(8):577–584.
  • Leypoldt JK, Loghman-Adham M, Jordan P, et al. Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations. Hemodial Int. 2012;16(1):20–30.
  • de Francisco AL, Sulowicz W, Klinger M, et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006;60(12):1687–1696.
  • Besarab A, Salifu MO, Lunde NM, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther. 2007;29(4):626–639.
  • Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23(5):969–979.
  • Provenzano R, Besarab A, Macdougall IC, et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007;67(5):306–317.
  • Fliser D, Dellanna F, Koch M, et al. The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemp Clin Trials. 2011;32(6):786–792.
  • Methoxy polyethylene glycol epoetin beta Phase 3 registered trials. 2015. [ cited 2015 Aug 4]. Available from: https://clinicaltrials.gov/
  • Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007;50:989–1000.
  • Levin NW, Fishbane S, Cañedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for hemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–1421.
  • Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646.
  • Spinowitz B, Coyne DW, Lok CE, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28:280–289.
  • Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009–4017.
  • Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable hemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654–3661.
  • Oh J, Joo KW, Chin HJ, et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci. 2014;29(1):76–83.
  • Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26(5):1083–1089.
  • Dellana F, Winkler RE, Bozkurt F, et al. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract. 2011;65(1):64–72.
  • Locatelli MS, Menegato AM, Villa G, et al. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia. J Nephrol. 2013;26(6):1114–1121.
  • Bastos K, Lucarelli LA, De Francesco-Daher E, et al. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis. Int Urol Nephrol. 2013;45(5):1355–1364.
  • Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3:337–347.
  • Kessler M, Martínez-Castelao A, Siamopoulos KC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. Hemodial Int. 2010;14(2):233–239.
  • Cianciaruso B. on behalf of the ORION study group. Experience in daily clinical practice of switching patients with chronic kidney disease (CKD) not on dialysis from darbepoetin alfa to once monthly C.E.R.A. PO2336 [Abstract]. J Am Soc Nephrol. 2010;21:704A.
  • Campistol JM, Carreño A, Morales JM, et al. Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation. 2013;95(2):e6–e10.
  • Chanu P, Gieschke R, Charoin JE, et al. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol. 2010;50(5):507–520.
  • Mircera (methoxy polyethylene glycol-epoetin beta) [prescribing information]. South San Francisco, CA: Hoffmann-La Roche; 2014.
  • Jelkmann W. The ESA scenario gets complex: from biosimilar epoetins to activin traps. Nephrol Dial Transplant. 2015;30(4):553–559.

• A cutting-edge review summarizing current knowledge about available and investigational anti-anemic therapies.

  • Cano F, Alarcon C, Azocar M, et al. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol. 2011;26(8):1303–1310.
  • Wedekin M, Ehrich JH, Pape L. Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta. Pediatr Transplant. 2011;15(3):329–333.
  • Weinreich T, Leistikow F, Hartmann HG, et al. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int. 2012;16(1):11–19.
  • Choi P, Farouk M, Manamley N, et al. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study. Adv Ther. 2013;30(11):1007–1017.
  • Chen CY, Hsu HJ, Lin YY, et al. Subcutaneous continuous erythropoietin receptor activator conversion provides practical advantages and potential convenience for peritoneal dialysis patients. Perit Dial Int. 2011;31(5):592–595.
  • Koch M, Henrich D, Faust J, et al. Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial. Clin Nephrol. 2012;78(3):189–197.
  • Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant. 2014;2014:179705.

• A prospective observational trial under real-life conditions, reporting stable hemoglobin (Hb) levels in kidney transplant recipients with once-monthly MPG-EPO therapy.

  • Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68(3):1337–1343.

• A detailed description of Hb cycling during recombinant human erythropoietin treatment in HD patients.

  • Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008;3:133–138.
  • Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191.
  • Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2006;20:479–487.
  • Locatelli F, de Francisco A, Deray G, et al. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract. 2014;128:323–332.
  • Forni V, Bianchi G, Ogna A, et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrol. 2013;14:157.

••A sophisticated analysis of the reticulocyte and Hb kinetics and variability under different ESAs and administration intervals in HD patients.

  • Choy BY, Lam MF, Yip T, et al. Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients. Nephrology (Carlton). 2013;18(8):533–538.
  • Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anemia and maintains hemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26:3980–3986.
  • Heidenreich S, Leistikow F, Zinn S, et al. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investig. 2012;32(2):99–110.
  • Padullés-Zamora N, Comas-Sugrañes D, Pineda-Yuste Mdel M, et al. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease. Nefrologia. 2012;32(2):221–227.
  • Koch M, Treiber W, Fliser D. Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study. Clin Drug Investig. 2013;33(10):699–706.
  • Selby NM, Fonseca SA, Fluck RJ, et al. Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int. 2012;32(2):177–182.
  • Mann JF, de Francisco A, Nassar G, et al. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76(1):9–15.
  • Martínez-Castelao A, Cases A, Coll E, et al. C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II. Nefrologia. 2015;35(1):80–86.
  • Choi JY, Yang CW, Kim YH, et al. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients. Kidney Blood Press Res. 2013;37(4–5):259–268.
  • Sánchez-Escuredo A, Batista F, Cases A, et al. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients. Transplant Proc. 2015;47(1):73–75.
  • Sánchez-Fructuoso AI, Ruiz JC, Torregrosa JV, et al. AnemiaTrans Study Group. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study. Adv Ther. 2012;29(11):979–991.
  • Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011;80(3):240–244.

• An important overview of hepcidin regulation and its potential role in CKD-related anemia.

  • Sasaki Y, Noguchi-Sasaki M, Matsuo-Tezuka Y, et al. Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol. 2014;99(5):561–569.
  • Sasaki Y, Noguchi-Sasaki M, Yasuno H, et al. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol. 2012;96(6):692–700.
  • Kakimoto-Shino M, Toya Y, Kuji T, et al. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Ther Apher Dial. 2014;18(5):421–426.
  • Morikami Y, Fujimori A, Okada S, et al. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial. 2014;18(5):414–420.
  • Shoji S, Inaba M, Tomosugi N, et al. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol. 2013;90(3):237–244.
  • Takasawa K, Tomosugi N, Takaeda C, et al. Regulation of hepcidin-25 by short- and long-acting rhEPO may be dependent on ferritin and predict the response to rhEPO in hemodialysis patients. Nephron Extra. 2014;4(1):55–63.
  • Kuji T, Toya Y, Fujikawa T, et al. Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: a randomized study. Ther Apher Dial. 2015;19(2):131–137.
  • Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73(2):94–103.

••Detailed evaluation of MPG-EPO`s safety profile in a pooled population comprising all patients from the completed phase II and phase III MPG-EPO studies.

  • Oh DJ. Anaphylaxis following the intravenous administration of continuous erythropoietin receptor activator in a haemodialysis patient. Nephrology (Carlton). 2014;19(5):304.
  • Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013;30(7):1729–1734.
  • Dávila Fajardo CL, Peña Ortega M, Cabeza Barrera J, et al. Methoxy polyethylene glycol-epoetin beta (Mircera) in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins. Nefrologia. 2010;30(3):372–373.
  • Vankar SG, Dutta P, Kohli HS, et al. Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis. Indian J Med Res. 2014;139(1):112–116.
  • Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4:470–480.
  • Palmer SC, Saglimbene V, Mavridis D, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;12:CD010590.

• A systematic review reasoning that there is currently insufficient evidence to suggest the superiority of any erythropoiesis-stimulating agent (ESA) formulation based on available safety and efficacy data.

  • Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs. 2013;73(2):117–130.
  • Macdougall IC, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81:727–732.

• An in-depth review summarizing current knowledge with respect to etiology and therapy of antibody-mediated pure red cell aplasia.

  • Lim SK, Bee PC, Keng TC, et al. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator. Clin Nephrol. 2013;80(3):227–230.
  • Pannier A, Jordan P, Dougherty FC, et al. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. Curr Med Res Opin. 2007;23(12):3025–3032.
  • Esposito C, Abelli M, Sileno G, et al. Effects of continuous erythropoietin receptor activator (CERA) in kidney transplant recipients. Transplant Proc. 2012;44(7):1916–1917.
  • Inal S, Gölbaş C, Oneç K, et al. Methoxy polyethylene glycol-epoetin beta (CERA) induced restless legs syndrome. Ther Apher Dial. 2012;16(4):378–379.
  • Galenica and Roche enter into exclusive license agreement for the commercialisation of Mircera® in the US. Galenica media releases. 2015. [ cited 2015 Aug 4]. Available from: http://www.galenica.com/en/medien/medienmitteilungen/2015/20150528_4356928162_meldung.php
  • Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm. 2014;36(6):1115–1125.
  • Chow JS, Rayment G, Britos V, et al. Change process during synchronised conversion to a once-monthly erythropoiesis-stimulating agent (ESA) administration at a single satellite haemodialysis unit. J Ren Care. 2012;38(4):191–201.
  • Schiller B, Doss S, De Cock E, et al. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Hemodial Int. 2008;12(4):441–449.

• A pioneer study demonstrating that use of a once-monthly ESA to correct anemia in dialysis patients may provide substantial time, resource, and cost savings.

  • Saueressig U, Kwan JT, De Cock E, et al. Healthcare resource utilization for anemia management: current practice with erythropoiesis- stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif. 2008;26(6):537–546.
  • De Cock E, Dellanna F, Khellaf K, et al. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries. J Med Econ. 2013;16(5):648–656.
  • Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res. 2014;6:319–330.
  • Rieger J, Krummel T, Petitjean P, et al. Switch of methoxy-polyethylene-glycol-epoetin beta to darbepoetin alfa in 263 dialysis patients. Ann Pharm Fr. 2015. [Epub ahead of print].
  • Otsuka T, Sakai Y, Yui S, et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. J Nippon Med Sch. 2015;82(1):21–26.
  • Donck J, Gonzalez-Tabares L, Chanliau J, et al. Preservation of anemia control and weekly ESA dosage after conversion from PEG-epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study. Adv Ther. 2014;31(11):1155–1168.
  • Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opin Pharmacother. 2009;10(9):1509–1514.

••A critical review highlighting potential benefits of MPG-EPO treatment for renal anemia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.